An official website of the United States government
A Study of Language Interpretation Solutions for People With Breast or Gastrointestinal Cancer
Trial Status: active
This clinical trial compares remote audio consecutive, video consecutive and simultaneous medical interpreting for providing accurate information about participants’ cancer and treatment patients with breast or gastrointestinal cancer who speak Spanish or Mandarin. Medical interpreting can be consecutive (the interpreter waits for the speaker to finish, then interprets) or simultaneous (the interpreter interprets while the speaker speaks). Remote consecutive medical interpreting (RCMI) is completed over the phone, remote consecutive video medical interpreting (RCVI) is completed using video and remote simultaneous medical interpreting (RSMI) uses video-conferencing technology. It is not yet known if RCMI, RCVI or RSMI provides the most accurate interpretation for patients with breast or gastrointestinal cancer who speak Spanish or Mandarin.
Inclusion Criteria
PHASE 1 PATIENTS: Age >= 18 years (per electronic medical record [EMR])
PHASE 1 PATIENTS: Preferred language for healthcare is Spanish or Mandarin (per self-report)
PHASE 1 PATIENTS: Limited English proficient; cannot speak English “very well” (per self-report)
PHASE 1 PATIENTS: Diagnosis of breast or gastrointestinal cancer (per EMR)
PHASE 1 PATIENTS: Will be visiting Memorial Sloan Kettering (MSK) oncology team for the first or second appointment (per EMR)
PHASE 1 PATIENTS: Agrees to be audio-recorded (per self-report)
PHASE 1 PROVIDERS: Breast or gastrointestinal cancer provider who sees patients (e.g., breast or gastrointestinal oncologists, advanced practice providers, and/or nurses)
PHASE 1 PROVIDERS: Does not speak Spanish and/or Mandarin; providers who speak one language and not the other may participate (e.g., speaks Spanish but not Mandarin) (per self-report)
PHASE 1 PROVIDERS: Agrees to be audio-record (per self-report)
PHASE 2: Is a staff member who works/worked in one of the study clinic sites during the period of phase 1 RCT study activities
PHASE 2: Agrees to be audio-recorded (per self-report)
Exclusion Criteria
PHASE 1 PATIENTS: Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient’s care team, or study team)
PHASE 1 PATIENTS: Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team)
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06721065.
I. To assess differences in interpreting errors (primary outcome), and appointment adherence (Electronic Health Record), patient knowledge of treatment/exit instructions (questionnaire, transcript analysis), patient-provider relationship (Perceived Efficacy in Patient-Physician Interactions scale) and efficiency by utterance ( Immigrant Health and Cancer Disparities [IHCD] Timing/Efficiency Tool) (secondary outcomes) with 576 Spanish- and Mandarin-speaking breast or gastrointestinal cancer outpatients with limited English proficiency randomized across three interpretation modalities (RSMI ["UN-style"] versus (vs.) RCMI ["audio consecutive"] vs. RCVI ["video consecutive"]).
II. To examine data on integrating host institution and systems factors/policies into the intervention, and implementation potential, through the exploration of the following: facilitators of and barriers to intervention delivery, and intervention sustainability after study completion; and ii) how the interventions and their delivery could be refined to improve future adoption and sustainability via quantitative and qualitative data collection
with 60 patient (previously enrolled phase 1 randomized controlled trial [RCT] participants) and 40 clinician, administrator, and staff surveys, then 40 in-depth interviews (patients and clinic staff).
EXPLORATORY OBJECTIVE:
I. To assess differences in interpreting errors and efficiency by utterances between RSMI and artificial intelligence (AI)-RSMI and gauge the potential acceptability of AI-RSMI with patient and facility surveys.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive RSMI for up to 3 visits with their medical oncologist on study. Patients have their visits audio recorded and may complete an interview after their last study visit.
ARM II: Patients receive RCMI for up to 3 visits with their medical oncologist on study. Patients have their visits audio recorded.
ARM III: Patients receive RCVI for up to 3 visits with their medical oncologist on study. Patients have their visits audio recorded.
Trial PhaseNo phase specified
Trial Typehealth services research
Lead OrganizationMemorial Sloan Kettering Cancer Center
